Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02626130 · ClinicalTrials.gov registry record · Early Phase 1
Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer
A Early Phase 1 study of Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer AJCC v7, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT02626130: Completed Early Phase 1 study of Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer AJCC v7, sponsored by M.D. Anderson Cancer Center.
NCT02626130 is a Early Phase 1 study of Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer AJCC v7 that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 29 participants, below the 203-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02626130, a Early Phase 1 study of Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer AJCC v7, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized pilot clinical trial studies the side effects of tremelimumab with or without tissue cryoablation in treating patients with kidney cancer that has spread to other places in the body. Tremelimumab binds to a protein called cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which is found on the surface of T cells (a type of white blood cell). Tremelimumab may block CTLA-4 and help the immune system kill cancer cells. Cryoablation is a procedure that uses a hollow, thin tube called a cryoprobe to freeze and destroy cancer tissue. It is not yet known whether tremelimumab with or without cryoablation is effective in treating patients with kidney cancer.
Primary Outcome
Safety will be recorded through the incidence of adverse events, serious adverse events and specific laboratory abnormalities (worst grade) in each treatment arm. Descriptive statistical analyses will be performed to summarize the incidence of adverse events.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- PROCEDURE Therapeutic Conventional Surgery
- PROCEDURE Cryosurgery
- BIOLOGICAL Tremelimumab
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2016-03-30 |
| Est. Completion | 2022-06-20 |
| Phase | Early Phase 1 |
What the finished NCT02626130 record still lists
NCT02626130 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 203-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (86% lower).
The record links to 3 conditions, with Clear Cell Renal Cell Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02626130 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02626130 about?
NCT02626130 is a clinical study titled "Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer". This randomized pilot clinical trial studies the side effects of tremelimumab with or without tissue cryoablation in treating patients with kidney cancer that has spread to other places in the body. Tremelimumab binds to a protein called cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which is...
What is the current status of trial NCT02626130?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 29 participants. The study started on 2016-03-30. Estimated completion is 2022-06-20.
What conditions does trial NCT02626130 study?
This clinical trial studies the following conditions: Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7, Metastatic Renal Cell Cancer.
What interventions are being tested in trial NCT02626130?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Therapeutic Conventional Surgery (PROCEDURE), Cryosurgery (PROCEDURE), Tremelimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02626130?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02626130 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clear Cell Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02626130's enrollment target sits among peer trials
29 37th of 45 higher than 9 of 45 other Clear Cell Renal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Clear Cell Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery
ACTIVE NOT RECRUITING · Early Phase 1
-
Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer
COMPLETED · Early Phase 1
-
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
RECRUITING · Phase 2
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
-
An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer
RECRUITING · Phase 2
-
Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI